Neurology
Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.
NeuroOne to Host Investor Webinar Following Recent FDA Clearance
NeuroOne Medical Technologies will hold a virtual investor webinar on October 7, 2025, to discuss business operations and recent FDA clearance, highlighting the company's progress in developing neurological disorder treatments.
New Research Reveals Menopause's Significant Impact on Multiple Sclerosis Symptoms and Comorbidities
Groundbreaking research presented at the ECTRIMS 2025 conference demonstrates how hormonal changes during menopause influence both initial symptoms and comorbidities in women with multiple sclerosis, potentially guiding future treatment development.
Menstrual Migraine Crisis Demands New Treatment Approaches as Health Tech Offers Hope
Millions of women suffer from debilitating menstrual migraines that require specialized hormonal-based treatments and benefit from emerging health technology solutions for better management.
Clene's CNM-Au8 Shows Promising Brain Energy Improvements in Multiple Sclerosis Patients
Clene Inc. presented positive trial results demonstrating that its investigational therapy CNM-Au8 significantly improved brain energy metabolism in multiple sclerosis patients, potentially offering a new approach to slowing disease progression by addressing underlying bioenergetic failure.
Creative Biolabs Launches Advanced Antibody Tools for Neuroscience Research
Creative Biolabs has developed specialized antibody products targeting key neurological proteins that could accelerate research into neurodegenerative diseases, movement disorders, and synaptic function.
Clene's CNM-Au8 Shows Promise in Addressing Cellular Dysfunction in Parkinson's Disease
Clene Inc.'s investigational therapy CNM-Au8 demonstrates potential to improve mitochondrial health and reduce inflammation in Parkinson's disease models, offering new hope for addressing the underlying cellular mechanisms driving neurodegeneration.
UCLA Smart Pen Achieves 96% Accuracy in Early Parkinson's Detection
A UCLA-developed smart pen demonstrates 96.22% efficacy in detecting Parkinson's disease during early stages, potentially revolutionizing diagnosis and treatment effectiveness.
Neuroscience Breakthrough Offers New Hope for Locked-In Syndrome Patients and Consciousness Research
Dr. Berenika Maciejewicz's research provides a new diagnostic framework for detecting consciousness in locked-in syndrome patients, with significant implications for brain-computer interfaces and neurological care.
Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8®
Clene Inc. is progressing toward submitting a New Drug Application for its ALS treatment CNM-Au8® by late 2025, potentially offering new hope for patients with this devastating neurodegenerative disease.
MadSci Secures $10 Million Oversubscribed Seed Funding for Hydrocephalus Innovation
MedTech startup MadSci's oversubscribed $10 million seed round signals strong investor confidence in its SmartShunt System, which aims to address decades of unmet needs in hydrocephalus treatment through integrated diagnostic and therapeutic technology.
Clene's CNM-Au8 Shows Promise in Parkinson's Disease Preclinical Study
Clene Inc. presented preclinical data demonstrating its investigational drug CNM-Au8 improves mitochondrial function and reduces inflammation in Parkinson's disease models, potentially offering a new neuroprotective treatment approach.
New Research Identifies SOX6 Protein as Potential Key to Myelin Repair in Multiple Sclerosis
Groundbreaking research published in Cell reveals that targeting the SOX6 protein could enable myelin repair in multiple sclerosis patients, potentially opening new therapeutic avenues for the neurodegenerative disease.
InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease
InFlectis BioScience and Aix Marseille Université have demonstrated that lead compound IFB-088 shows efficacy in animal models of axonal Charcot-Marie-Tooth disease type 2A, expanding its potential to address multiple CMT subtypes with no approved treatments.
Study Links Head Injuries to Increased Brain Cancer Risk, Driving Treatment Research
A Mass General Brigham study of 75,000 patients reveals traumatic brain injuries elevate malignant brain tumor risk, highlighting the importance of ongoing treatment development by companies like CNS Pharmaceuticals Inc.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Blocking Brain Damage from Glioblastoma May Slow Tumor Growth and Extend Cognitive Function
New research from University College London suggests that preventing brain damage caused by glioblastoma could significantly slow tumor progression and preserve cognitive function longer in patients.
Clene Inc. Advances Toward NDA Submission for ALS Treatment CNM-Au8, Extends Financial Runway
Clene Inc. is preparing to submit a New Drug Application for its ALS treatment candidate CNM-Au8 by year-end 2025 while securing financial stability through recent financing that extends its cash runway into early 2026.
Lantern Pharma Launches AI Tool predictBBB.ai to Revolutionize CNS Drug Development with 94% Accuracy
Lantern Pharma's new AI platform predictBBB.ai addresses the critical challenge of blood-brain barrier permeability in drug development, potentially accelerating treatments for neurological diseases with unprecedented 94% prediction accuracy.
Study Reveals B-Vitamin Supplements Could Offer New Hope for Parkinson’s Disease Patients
A recent study highlights the potential of B-vitamin supplements in addressing some medical needs of Parkinson’s disease patients, suggesting a simple yet effective treatment option.
Clene Inc. Advances Toward FDA Submission for ALS Therapy with Promising Q2 2025 Results
Clene Inc. reports significant progress in its Q2 2025 results, targeting a year-end NDA submission for its ALS therapy, CNM-Au8, with sufficient cash runway into Q1 2026.
Understanding the Risks and Treatments of Benign Brain Tumors in Women
This article highlights the increased risk of benign brain tumors in women and the importance of recognizing early symptoms, while also discussing current treatment options and ongoing research efforts.
Oragenics Inc. Advances Toward Phase IIa Concussion Trial with ONP-002
Oragenics Inc. (NYSE American: OGEN) is making significant progress with its lead candidate, ONP-002, aiming to become the first FDA-approved pharmacological treatment for concussion, highlighting the potential of its intranasal delivery technology in transforming neurological care.
Quantum BioPharma's PET Tracer Shows Promise in Monitoring Myelin Integrity in Multiple Sclerosis
Quantum BioPharma Ltd.'s collaboration with Massachusetts General Hospital has yielded a PET tracer capable of detecting MS lesions invisible to conventional MRI, marking a significant advancement in the monitoring and treatment of multiple sclerosis.
Annovis Bio Inc. Secures Comprehensive Patent Coverage for Buntanetap, Enhancing Treatment Prospects for Neurodegenerative Diseases
Annovis Bio Inc. has expanded its patent portfolio to cover a new crystalline form of buntanetap, promising improved stability and bioequivalence for treating neurodegenerative diseases like Alzheimer's and Parkinson's, with protection extending through 2046.
Clene Inc. to Showcase Neurodegenerative Disease Treatments at Canaccord 45th Annual Growth Conference
Clene Inc. will present its innovative treatments for neurodegenerative diseases at the Canaccord 45th Annual Growth Conference, highlighting potential advancements in ALS and MS therapy.
Lantern Pharma Introduces AI Tool PredictBBB.ai(TM) with 94% Accuracy in Predicting Blood-Brain Barrier Permeability
Lantern Pharma's new AI module, predictBBB.ai(TM), significantly enhances the prediction of small molecules' ability to cross the blood-brain barrier, addressing a major challenge in drug development.
Exploring the Link Between TMJ/TMD and Severe Headaches Through Neuromuscular Dentistry
A new article highlights the connection between TMJ/TMD disorders and severe headaches, offering insights into treatment options like Sphenopalatine Ganglion Blocks and Neuromuscular Dentistry.
AI-Based Speech Tool Offers Early Detection Potential for Parkinson’s Disease
A new AI-based speech screening tool developed by computer scientists could revolutionize the early detection of Parkinson’s disease, offering patients a better chance at effective management of the condition.
Oragenics Inc. Advances ONP-002 Phase IIa Trial with Southern Star Research for Concussion Treatment
Oragenics Inc. partners with Southern Star Research to conduct a Phase IIa trial for ONP-002, an intranasal therapy aimed at treating mild traumatic brain injuries, highlighting a significant step towards addressing the unmet needs in concussion care.